The fusion protein ch14.18-IL2 contains a chimeric anti-GD2 antibody (ch14.18) tethered to recombinant human IL-2.64 The IL-2 portion of the immunocytokine activates NK cells via the IL-2 receptor instead of the Fcγ receptor as seen with dinutuximab.65,66 In addition, it has exhibited activity in NB-bearing mice via NK-mediated effects and enhanced antitumor activity when compared to anti-GD2 antibody in combination with IL-2.67,68 Thus we examined whether combined treatment with ch14.18-IL2 and an inhibitor of CD38 would enhance the cytotoxic effects of NK cells. This evidence concerns the gene CD38 and neuroblastoma.